A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Trial of Allisartan Isoproxil in Essential Hypertensive Population at Low- Medium Risk

作者：Li, Ying; Li, Xiao-hui; Huang, Zhi-jun; Yang, Guo-ping; Zhang, Guo-gang; Zhao, Shui-ping; Guo, Ying; Lu, Shi-juan; Ma, Jian-lin; Meng, Fan-bo; Chen, Ping; Yuan, Hong^*

来源：PLos One, 2015, 10(2): e0117560.

DOI：10.1371/journal.pone.0117560

• CONVERTING ENZYME-INHIBITORS
• BLOOD-PRESSURE
• LOSARTAN POTASSIUM
• PREVALENCE
• ANTAGONIST
• ASSOCIATION
• CHOLESTEROL
• MORTALITY
• PARALLEL
• SAFETY

Background @@@ Angiotensin II receptor blockers (ARBs) is a well-tolerated class of antihypertensive agents, exhibiting effective antihypertensive and cardiovascular protective function. The objective of the study was to examine the efficacy and safety of Allisartan Isoproxil, a newly developed, selective, nonpeptide blocker of the angiotensin II type 1 receptor (AT1R), in essential hypertensive patients at low-medium risk.

• 出版日期2015-2-18
• 单位海南省人民医院; 湖南省人民医院; 吉林大学; 汕头市中心医院